Studies have suggested circulating free DNA (cfDNA) as an alternative to tissue analysis for the detection of KRAS mutations.12, 13 It has reported that cfDNA is an informative, inherently specific, and highly sensitive biomarker for mCRC and high concordance rates exist between cfDNA and tumor tissues.14, 15, 16. This evidence concerns the gene KRAS and neoplasm.